AM-Pharma is backed by a strong syndicate of international investors, including Venture Capital Funds and Corporate Venture Funds. To date, the company has raised over €250 million in equity and debt.
In March 2020, AM-Pharma increased its funding to €163 million to conduct its global Phase III REVIVAL pivotal trial of recombinant alkaline phosphatase in sepsis-associated acute kidney injury. Additional funds of €47 million have been added to initial €116 million that was raised from an international syndicate of investors. Lead investors were the US-based Cowen Healthcare Investments and the European Investment Bank (EIB).
In addition, the Dutch Ministry of Economic Affairs (Netherlands Enterprise Agency – RVO) granted AM-Pharma non-dilutive financing.